Alkermes (ALKS) Total Non-Current Liabilities (2011 - 2026)
Alkermes (ALKS) posted quarterly Total Non-Current Liabilities of $2.4 billion for Q2 2026, up 327.89% year-over-year from $572.2 million in Q2 2025, and up 2.14% quarter-over-quarter from $2.4 billion in Q1 2026.
Alkermes (ALKS) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Total Non-Current Liabilities for 16 consecutive years, with $2.4 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Non-Current Liabilities rose 327.89% year-over-year to $2.4 billion; the TTM figure through Jun 2026 stood at $2.4 billion (up 327.89% YoY), while the FY2025 annual figure was $606.7 million, up 13.49% from the prior year.
- Total Non-Current Liabilities advanced to $2.4 billion in Q2 2026 per ALKS's latest filing, from $2.4 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $2.4 billion in Q2 2026 and bottomed at $511.5 million in Q1 2025.
- Historically, Total Non-Current Liabilities has averaged $945.5 million across 5 years, with a median of $857.4 million in 2022.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities tumbled 39.5% — and 2026, when it surged 368.59%.
- Alkermes' Total Non-Current Liabilities stood at $877.8 million in 2022, then grew by 0.66% to $883.7 million in 2023, then sank by 39.5% to $534.6 million in 2024, then rose by 13.49% to $606.7 million in 2025, then soared by 303.55% to $2.4 billion in 2026.
- Business Quant data shows ALKS's Total Non-Current Liabilities at $2.4 billion in Q2 2026, $2.4 billion in Q1 2026, and $606.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn | 2.45 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.45 Bn |
| Mar 31, 2026 | 2.40 Bn |
| Dec 31, 2025 | 606.69 Mn |
| Sep 30, 2025 | 539.33 Mn |
| Jun 30, 2025 | 572.18 Mn |
| Mar 31, 2025 | 511.54 Mn |
| Dec 31, 2024 | 534.57 Mn |
| Sep 30, 2024 | 810.56 Mn |
| Jun 30, 2024 | 874.54 Mn |
| Mar 31, 2024 | 820.17 Mn |
| Dec 31, 2023 | 883.66 Mn |
| Sep 30, 2023 | 870.03 Mn |
| Jun 30, 2023 | 858.53 Mn |
| Mar 31, 2023 | 868.66 Mn |
| Dec 31, 2022 | 877.84 Mn |
| Sep 30, 2022 | 856.19 Mn |
| Jun 30, 2022 | 829.89 Mn |
| Mar 31, 2022 | 858.55 Mn |
| Dec 31, 2021 | 868.25 Mn |
| Sep 30, 2021 | 867.15 Mn |